Editas Medicine Inc Dossier - Source-backed chat

Editas Medicine Inc

EDITNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.70

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $2.52Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $387M

Enterprise Value $260.9M

Shares Outstanding 153.6M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Editas Medicine has successfully stabilized its financial profile and sharpened its strategic focus by pivoting from complex ex vivo therapies (such as the discontinued reni-cel program) to high-value, commercially attractive in vivo gene editing. The company's lead candidate, EDIT-401, targets heterozygous familial hypercholesterolemia (HeFH) and broader hyperlipidemia using a highly differentiated gene upregulation strategy. Preclinical data in non-human primates has demonstrated a robust and durable ~90% mean reduction in LDL-C, Lp(a), and ApoB with a favorable safety profile. Backed by a newly secured capital runway extending into Q3 2027 (further bolstered by a $125 million public offering in May 2026), Editas presents an asymmetric risk-reward profile ahead of its critical late-2026 clinical proof-of-concept catalyst.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$1.00

Mean target$5.78

High · most bullish analyst$15.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.0020%

The initiation of the EDIT-401 clinical trial is delayed due to regulatory hurdles or manufacturing bottlenecks. When early data is released, it shows either suboptimal LDL-C reduction in humans or unexpected off-target toxicities (such as severe liver enzyme elevations). The warrants expire unexercised, and the company is forced to raise highly dilutive capital in mid-2027 to sustain operations, severely depressing the stock price.

Base CaseCentral scenario

$5.4055%

Editas successfully files its Australian CTN by mid-2026 and initiates the Phase 1/2 trial of EDIT-401. Early proof-of-concept data by year-end 2026 demonstrates meaningful, competitive LDL-C reductions (e.g., 50-70%) with a clean safety profile, establishing clinical viability. The company maintains its disciplined cash burn, keeping its runway intact into late 2027, while slowly advancing its broader in vivo pipeline.

Bull CaseUpside scenario

$8.0025%

EDIT-401's first-in-human trial in Australia initiates smoothly in late 2026, delivering early human proof-of-concept data that replicates the ~90% LDL-C reduction seen in preclinical primate models. This clinical validation triggers the exercise of the May 2026 warrants, infusing an additional $194.4 million in cash and extending the runway well into 2029. The clinical success attracts a major biopharma partnership, validating the in vivo upregulation platform and driving significant upfront licensing payments.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated in vivo gene upregulation strategy targeting the LDLR gene, offering a potential one-time curative treatment for hyperlipidemia.
Strong preclinical proof-of-concept with ~90% mean LDL-C, Lp(a), and ApoB reductions in non-human primates.
Substantially improved cost structure and narrowed net losses following the strategic discontinuation of the ex vivo reni-cel program and workforce reductions.
Secured cash runway into at least the third quarter of 2027, reinforced by the $125 million gross proceeds from the May 2026 public offering.
Exclusive licensing rights to the Broad Institute's foundational Cas12a and Cas9 patent estates for human medicines.

Key Investment Risks

High clinical development risk as the lead candidate EDIT-401 transition from preclinical models to first-in-human trials.
Intense competition in the cardiovascular gene editing space from well-capitalized peers (e.g., Verve Therapeutics, Eli Lilly).
Ongoing intellectual property litigation risks, as the CVC group retains the right to appeal the USPTO's patent interference decisions favoring the Broad Institute.
Lack of recurring product revenue, leaving the company entirely dependent on capital markets and partnership milestones.

Thesis Invalidation Triggers

Failure to submit the Australian CTN or receive regulatory clearance to initiate the EDIT-401 trial in 2026.
Early human clinical data for EDIT-401 showing an unfavorable safety profile, such as severe, dose-limiting liver toxicity.
Inability to replicate therapeutically meaningful LDL-C reductions in human subjects.
An adverse final ruling in CRISPR/Cas9 patent appeals that compromises Editas' exclusive licensing foundation.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.